IMPLANET Reports its 2024 First-Quarter Revenue

Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of technological medical equipment, today announces its revenue for the first quarter of 2024.

Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: “The first quarter of 2024 was in line with previous quarters, with good sales momentum in our domestic market, a ramp-up in our medical equipment distribution activity, and the gradual reinvigoration of our international activities. Strengthening our presence through the deployment of our innovative solutions remains one of our priorities for the months ahead, and has already seen major progress with the ongoing reorganization of our US subsidiary. With this in mind, 2024 should see the finalization of the registration of our existing products under the European MDR regulation, the commercial launch of our proprietary JAZZ range in China, and the launch of a novel range of hybrid posterior fixation for the European market, co-developed by Sanyou Medical and IMPLANET R&D teams.”

2024 First quarter

Revenue (in € thousands – IFRS1)	2024 Q1	2023 Q1	Change %
France	1,032	942	+10%
United States	314	459	-32%
Rest of the world	618	674	-8%
Spine revenue	1,964	2,075	-5%
Medical equipment (SMTP)	247	124	+100%
Services (MADISONTM)	12	9	+41%